Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus enfortumab vedotin with or without investigational agents in first-line metastatic urothelial carcinoma
NL-OMON59757Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of pembrolizumab and enfortumab vedotin in transitional cell carcinoma (TCC) (2 arms), sponsored by Merck & Co. Primary endpoint: Primary endpoint(s). Started May 2023; status: completed.
02
Drugs
pembrolizumabenfortumab vedotin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON59757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59757.